# QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.

> **NCT03828227** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **GERCOR - Multidisciplinary Oncology Cooperative Group** · enrollment: 49 (actual)

## Conditions studied

- Elderly Patients
- Metastatic Colorectal Cancer
- Quality of Life

## Interventions

- **DRUG:** OPTIMOX-bevacizumab
- **DRUG:** Capecitabine plus bevacizumab

## Key facts

- **NCT ID:** NCT03828227
- **Lead sponsor:** GERCOR - Multidisciplinary Oncology Cooperative Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-06-14
- **Primary completion:** 2023-11-10
- **Final completion:** 2025-12
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2025-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03828227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03828227, "QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03828227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*